POTENTIAL ROLE OF LACTOFERRIN IN EARLY DIAGNOSTICS AND TREATMENT OF PARKINSON DISEASE

A.V. Sokolov1, 2, 3, I.V. Miliukhina1, Y.P. Belsky2, N.V. Belska2, V.B. Vasilyev4, 2

1 Institute of Experimental Medicine, Saint Petersburg, Russia;
2 Saint Petersburg State University, Saint Petersburg, Russia;
3 The Preclinical Translational Research Centre of the Almazov Centre, Saint Petersburg, Russia


Received: January 28, 2020 Revised: February 26, 2020 Accepted: March 3, 2020

Incidence of Parkinson disease progressively grows with increasing age and percentage of elderly people in the global population. Clear understanding of the causes of dopaminergic neurons’ death in Substantia nigra and Parkinson disease pathogenesis are currently absent, not speaking of an efficient therapy. However, an early diagnosis of dopaminergic neurons’ degeneration and prescription of dopamine replacement therapy significantly slow down the rate of symptoms’ progression. An increased concentration of iron in Substantia nigra of Parkinson disease patients has been shown in several studies. In this review we summarized the data concerning a potential significance of lactoferrin, the iron-binding protein of exocrine secretions and neutrophils, for early diagnosis and treatment of Parkinson disease. Salivary and lacrimal lactoferrin levels in Parkinson disease patients were higher than those observed in the control group. Plasma levels of lactoferrin inversely correlated with Parkinson disease severity even after treatment with Levodopa, a dopamine agonist, and with monoaminooxidase inhibitors. Lactoferrin levels in cerebrospinal fluid of Parkinson disease patients negatively correlated with the tumor necrosis factor-alpha concentration. Lactoferrin treatment of rodents with several experimental models of Parkinson disease (induced by rotenone, MPTP) protected neurons and mitigated the symptoms of neurodegeneration. Some contradictions about the positive effects of lactoferrin as a remedy in Parkinson disease animal models and possible participation of lactoferrin in accumulation of iron in neurons are discussed.

Keywords: Parkinson’s disease; lactoferrin; iron.

List of abbreviations
DA — dopamine; LF — lactoferrin; MPTP — 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD — Parkinson disease; SN — Substantia nigra; SNpc — Substantia nigra pars compacta.
Introduction

Parkinson disease (PD) is the major cause of slowly progressive parkinsonism, a clinical syndrome comprising combinations of motor and non-motor symptoms. The incidence of PD is estimated between 10 and 50 per 100,000 person-years, and its prevalence rate is approximately 0.3% of the entire population, affecting more than 1% of individuals above 60 years and up to 4% of those older than 80 years [1, 2]. The nigrostriatal dopamine (DA) system in aging shares important biological features with PD. Dopaminergic neurodegeneration in PD presents a complex biology of interacting factors. Many of those factors are also present during the aging of DA system. In normal aging a reduced viability of dopaminergic neurons is manifested as impaired function of the system, whereas additional contributions of genetic, environmental, factors are needed to reach the threshold for dopaminergic neurodegeneration in PD [3, 4]. In healthy aging selective accumulation of iron occurs in several brain regions and different cell types, with iron mostly bound to ferritin and neuromelanin. Iron is involved in quite a few cellular processes in the brain. Those include mitochondrial respiration, synthesis of myelin, DNA and neurotransmitters, oxygen transportation, and other components of cellular metabolism. Dysregulation of iron metabolism has been linked to the pathogenesis of several neurodegenerative disorders, including PD, and age-related accumulation of iron might be an important factor that contributes to neurodegenerative processes [5]. Iron has been shown to accumulate in Substantia nigra pars compacta (SNpc) in PD patients. Lees [6] studied micro-architecture of SN in patients with parkinsonism as compared with control cases of varying age. The lateral-ventral tier of SNpc was identified as selectively vulnerable to the loss of melanized dopaminergic neurons in PD. In patients with PD SNpc was identified as the site of iron accumulation, whereas in controls SN pars reticulata is rich in iron [7–9]. Overlapping of regions detected by iron-sensitive MRI and neuromelanin-sensitive MRI was shown in SN of individuals with PD and healthy controls. The lateral-ventral SNpc was identified as prone to iron accumulation [10].

The clinical application of iron chelators has a bright future in PD therapy [5]. To achieve a better follow-up the earliest possible start of PD treatment is proposed, when movement disorders are not severe [11, 12]. A number of studies in animal models have shown that lactoferrin (LF), a multifunctional iron-binding glycoprotein, provides neuroprotection against DA neuronal impairment by several mechanisms. Those are not limited to the regulation of iron metabolism, but may involve the inhibition of apoptosis or mitigation of oxidative stress and neuroinflammation [5].

Links between pathogenesis of PD and iron metabolism

The hypothesis of iron participation in the degeneration of dopaminergic neurons is based on the peculiarities of iron localization in the brain of PD patients. DA, the crucial neurotransmitter involved in PD, easily forms toxic metabolites. Indeed, even in physiological conditions the oxidation of DA by monoamine oxidase results in formation of hydrogen peroxide. Interaction between hydrogen peroxide and iron accumulated in dopaminergic neurons is known as the Fenton reaction producing hydroxyl radicals. These reactive oxygen species provoke oxidative stress featuring the destruction of lipids, proteins, nucleic acids and various antioxidants [13, 14]. Direct oxidative modification of ceruloplasmin with a drop of its ferroxidase activity in cerebrospinal fluid of PD patients is a vivid example of the causative link between the iron deposition in the central nervous system and the oxidative stress. [15]. Elevated level of intracellular iron induced ferroptosis, the programmed cell death associated with accumulation of lipid hydroperoxides produced in the presence of Fe(II). Moreover, the iron-catalyzed oxidation of DA formed 6-hydroxydopamine. Noteworthy, the latter is used as a neurotoxin to model PD in animals, since it induces iron release from ferritin and the production of reactive oxygen species [16, 17].

The pathognomonic sign of familial and sporadic PD is the presence of Lewy bodies. Those contain aggregates of alpha-synuclein, but also are stained in the iron-sensitive histochemical reaction [18]. Alpha-synuclein is mostly contained in presynaptic terminals and may be involved in the compartmentalization, storage, and recycling of neurotransmitters [19, 20]. The high-affinity iron-binding sites were identified in its structure: D121, N122, and E123 [21]. Experiments with wild-type and mutant form of alpha-synuclein (A30P, A53T, and E46K),
which is specific for familial cases of PD, showed that Fe(III) can induce fibrillation of both wild-type and mutant forms of the protein [22]. Under physiological conditions only about 4% of the soluble monomeric alpha-synuclein is phosphorylated, whereas the protein found in Lewy bodies of PD patients is phosphorylated by more than 90% [23]. The 119DPDNEA(pY)EMPSEEG132 phosphopeptide of alpha-synuclein, where Y residue was replaced with phosphothreonine (pY), possessed a marked selectivity for trivalent metal ions, e.g. Fe(III), in comparison with the non-modified peptide or the phosphoserine (pS) containing peptide: 119DPDNEAYEMP(pS)EEG132 [24, 25].

5’-untranslated region of mRNA encoding alpha-synuclein contains the steam-loop structure motif similar to the iron-responsive element of mRNA encoding H- and L-ferritin, ferroportin, and mitochondrial aconitase [26]. In the absence of iron, iron-regulatory proteins bind the iron-responsive element at the ferritin mRNA and block ferritin translation. In a cellular model with knockdown of iron-regulatory protein 1, which corresponds to the situation when iron-responsive element do not sense iron, the level of alpha-synuclein mRNA was up-regulated [27]. Depletion of intracellular iron by desferal decreased the level of alpha-synuclein mRNA [28]. This impact of the iron concentration on the regulation of alpha-synuclein synthesis does not seem coincidental if to take into account that both the recombinant protein and lysates of cells with alpha-synuclein overexpression demonstrate the activity of ferric reductase [29]. Overexpression of alpha-synuclein alters the activity of tyrosine hydroxylase, the key enzyme involved in DA synthesis [30].

In 1997 Logroscino and colleagues reported about an alteration of systemic iron metabolism in PD patients [31]. Comparing the latter with a corresponding age group of donors without clinical evidence of PD or other major neurologic or medical disorder revealed a significant decrease of serum iron and the total iron binding capacity, of transferrin and its iron saturation, and of ferritin. Although there was no difference between patients and controls in the overall dietary intake of iron, dietary iron was not related to serum iron. Moreover, there was also no difference between patients with PD who used Levodopa and those who did not, implying that the observed differences in circulating concentrations of iron and iron proteins were not related to dissimilarities in the treatment of PD [31]. The peculiarities of iron metabolism in PD observed in that study were consistent both with previous [32] and subsequent [33] investigations. Importantly, the level of plasma transferrin positively correlated with the severity of tremor in the tremor-dominant PD [34].

Links between lactoferrin and Parkinson disease

Studies of a connection between LF and the pathogenesis of PD started with an observation of the LF receptor higher content in mesencephalon samples obtained by autopsy from 8 patients with histologically confirmed PD in comparison with 13 individuals with no known history of psychiatric or neurological disorders [35]. This observation immediately placed a theoretical footing for a possible mechanism of pumping iron in the brain of patients with PD [36]. This contradicted the notion that the bacteriostatic activity of LF in exocrine secretions and neutrophils is based on its capacity to sequester iron, otherwise captured by microorganisms. Indeed, LF binds iron about 300 times more avidly than transferrin, but little is known about the regulation of iron release from LF in physiological conditions [37]. Further analysis of cellular distribution in mesencephalon demonstrated the high levels of LF in a large population of neurons in SN of control cases [38]. Quantitative analysis also demonstrated that patients with PD had higher LF levels in the surviving neurons of SN as compared with control cases. The authors conclude: “further studies will be necessary to elucidate whether LF acts as an iron scavenger and may represent a protective factor, or conversely, promotes excessive iron accumulation leading to oxidative damage in vulnerable neurons” [38]. In animals the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) destroys neurons in SN, containing most of the melanin, and causes a PD-like syndrome [39]. Treatment of mice with MPTP caused up-regulation of LF expression accompanied by the synthesis of antioxidant enzymes such as catalase and gamma-glutamyl cysteine synthetase, which may provide the protection of brain tissue from oxidative damage induced by the neurotoxin [40, 41]. This hypothesis is confirmed by an observation that LF plasma levels inversely correlated with PD severity even after treatment with Levodopa, the DA agonist, and monoaminooxidase inhibitors [42]. Noteworthy, the expression of gamma-glutamyl cysteine synthetase is under control of the nuclear factor erythroid 2-related factor 2, the synthesis of which is induced by LF [43, 44].

Several groups reported about the capacity of both iron-saturated and apo-forms of LF to cross the blood-brain barrier in vitro and in vivo [45–48]. These observations stimulated the studies of LF beneficial effects, when LF-coated nanoparticles were used to deliver drugs and constructions designed for gene therapy in animals with models of PD [49–53]. In parallel several studies demonstrated the anti-anxiety and stress-protective activity of LF mediated via the opioid system and its corticostatic activity [54–57].
Early in this century a peptide hormone hepcidin was discovered. It regulates the iron efflux from cells under inflammatory conditions and iron overload [58, 59]. Iron metabolism is affected by a number of pro-inflammatory cytokines on (e.g. tumor necrosis factor-alpha, interleukin-1beta, interleukin-6) mediated both by iron-regulatory proteins and by hepcidin. This process includes the up-regulation of divalent metal transporter 1 and down-regulation of ferroportin, the iron exporter [60]. Antianemic effect of LF is realized by decreasing IL-6, abrogating the endotoxin-mediated degradation of ferroportin and increasing ceruloplasmin ferroxidase activity [61–63]. Ferroxidase activity of ceruloplasmin prevents the ubiquitin-mediated degradation of ferroportin [64]. Participation of LF in iron regulation is also mediated via stabilization of iron-sensitive hypoxia-inducible factors-1 alpha and -2 alpha [65, 66]. These transcription factors up-regulate the synthesis of erythropoietin, which demonstrated neuroprotective effects distinct from its antianemic functions [67]. Indeed, intraperitoneal and nasal administration of LF to rodents protects the animals against neurodegeneration, including the rotenone-induced model of PD in rats [42]. These results are confirmed by other studies in which LF protected a culture of dopaminergic neurons from toxic effects of MPTP [67] or mice [69, 70] against the MPTP-induced neurodegeneration. In MPTP-treated mice the level of divalent metal transporter 1 in striatum became significantly higher in comparison with the control group, but after LF treatment it was substantially decreased [69]. The following scheme summarizes the effects of LF treatment in PD animal models, differing in the pathogenetic links affected.

The effects of LF and pro-inflammatory cytokines are inverse, which is evidenced by the negative correlation of LF and tumor necrosis factor-alpha levels in cerebrospinal fluid of PD patients [71]. Two recent studies independently suggested a potential usability of LF as non-invasive marker of PD [72, 73]. In fact, the levels of LF in saliva and tears of PD patients were higher than those observed in the control group. Using salivary and lacrimal LF as PD marker seems reasonable, since both fluids are easily obtained as compared with the blood samples and, which is more important, the levels of LF in these exocrine secretions are much higher than the level of oligomeric alpha-synuclein. The latter is widely used for PD diagnosing, but its prevalence in red blood cells, relatively low concentration in biological fluids and contradictory data of meta-analysis diminish its importance as a PD marker [74, 75].

Conflict of interest. The authors declare no conflict of interest in financial or any other sphere.

References


**Information about the authors / Сведения об авторах**

**Alexey V. Sokolov** — Doctor of Biological Sciences, Head of the Laboratory of Biochemical Genetics of the Department of Molecular Genetics, Institute of Experimental Medicine, Saint Petersburg, Russia; Professor of Chair of Fundamental Problems of Medicine and Medical Technology at Saint Petersburg State University, Saint Petersburg, Russia; Senior researcher of the Biochemical Research Department of the Preclinical Translational Research Centre, the Institute of Experimental Medicine of the Almazov Centre, Saint Petersburg, Russia. http://orcid.org/0000-0001-9033-0537. SPIN-code: 7427-7935. E-mail: biochemsokolov@gmail.com.

**Irina V. Miliukhina** — PhD, MD, Head of the Center of the Neurodegenerative Disorders, Institute of Experimental Medicine, Saint Petersburg, Russia. http://orcid.org/0000-0002-6433-542X. SPIN-code: 1767-2266. E-mail: milyukhinaiv@yandex.ru.

**Yury P. Belsky** — Doctor of Medical Sciences, Head of the Biochemical Research Department of the Preclinical Translational Research Centre, the Institute of Experimental Medicine of the Almazov Centre, Saint Petersburg, Russia. E-mail: belsky59@mail.ru.

**Алексей Викторович Соколов** — д-р биол. наук, заведующий лабораторией биохимической генетики отдела молекулярной генетики, ФГБНУ «Институт экспериментальной медицины», Санкт-Петербург; профессор кафедры фундаментальных проблем медицины и медицинских технологий ФГБУ ВПО «Санкт-Петербургский государственный университет», Санкт-Петербург; старший научный сотрудник Научно-исследовательского отдела Центра доклинических и трансляционных исследований Института экспериментальной медицины ФГБУ «НИИЦ им. В.А. Алма-Зова» Минздрава России, Санкт-Петербург. https://orcid.org/0000-0001-9033-0537. SPIN-код: 7427-7935. E-mail: biochemsokolov@gmail.com.

**Ирина Валентиновна Мильюхина** — канд. мед. наук, руководитель научно-клинического центра нейродегенеративных заболеваний, старший научный сотрудник, ФГБНУ «Институт экспериментальной медицины», Санкт-Петербург. http://orcid.org/0000-0002-6433-542X. SPIN-код: 1767-2266. E-mail: milyukhinaiv@yandex.ru.

**Юрий Павлович Бельский** — д-р мед. наук, руководитель Научно-исследовательского отдела Центра доклинических и трансляционных исследований Института экспериментальной медицины ФГБУ «НИИЦ им. В.А. Алма-Зова» Минздрава России, Санкт-Петербург. E-mail: belsky59@mail.ru.
Nataly V. Belska — Doctor of Medical Sciences, Leading Researcher of the Toxicology Research Department of the Preclinical Translational Research Centre, the Institute of Experimental Medicine of the Almazov Centre, Saint Petersburg, Russia. E-mail: natalybelska@yandex.ru.

Natalia Витальевна Бельская — д-р мед. наук, ведущий научный сотрудник Научно-исследовательского отдела токсикологии Центра доклинических и транслационных исследований Института экспериментальной медицины ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России, Санкт-Петербург. E-mail: natalybelska@yandex.ru.

Vadim B. Vasilyev — Doctor of Medical Sciences, Head of the Department of Molecular Genetics, Institute of Experimental Medicine, Saint Petersburg, Russia; Professor of Chair of Fundamental Problems of Medicine and Medical Technology at Saint Petersburg State University, Saint Petersburg, Russia. https://orcid.org/0000-0002-9707-262X. SPIN-code: 6699-6350. E-mail: vadim@biokemis.ru.

Вадим Борисович Васильев — д-р мед. наук, руководитель отдела молекулярной генетики, ФГБНУ «Институт экспериментальной медицины», Санкт-Петербург; профессор кафедры фундаментальных проблем медицины и медицинских технологий ФГБОУ ВПО «Санкт-Петербургский государственный университет», Санкт-Петербург. https://orcid.org/0000-0002-9707-262X. SPIN-код: 6699-6350. E-mail: vadim@biokemis.ru.

Corresponding author / Контактное лицо

Alexey V. Sokolov / Алексей Викторович Соколов
E-mail: biochemsokolov@gmail.com